Vortex Biotech Holdings Limited has announced the opening of its advanced laboratory facilities at Manchester Science Park. The new site significantly enhances the company's R&D and commercial delivery capacity and strengthens its position as a leader in liquid biopsy technologies for precision oncology.
The laboratories are designed to GLP-ready specifications, allowing future expansion into clinical trial support and commercial product and services development. The site also serves as the company's European hub for research partnerships, with planned collaborations in single-cell analysis, molecular profiling, and AI-driven data integration.
Backed by EMV Capital, Vortex' proprietary liquid biopsy platform isolates and enriches circulating tumor cells (CTCs) and other rare biomarkers from blood samples, enabling high-sensitivity cancer detection, monitoring, and translational research. The Manchester facility will accelerate the company's ongoing programs in clinical validation, biomarker discovery, and commercial services development.
The establishment of our laboratory at Manchester Science Park is a strategic step in expanding collaborations with leading academic and clinical institutions and positions the company for growth.
The Park's proximity to the University of Manchester, NHS Manchester Foundation Trust, and a thriving life sciences ecosystem provides direct access to world-class expertise, clinical samples, and translational infrastructure essential for advancing liquid biopsy into clinical practice."
Nigel Brooksby, Non-Executive Chairman, Vortex
To mark the opening, Vortex hosted a formal launch event on 26 January 2026 at its new Manchester facilities, bringing together regional stakeholders, investors, and members of the Greater Manchester innovation ecosystem. The event included presentations from the Vortex management team and from EMV Capital, the deep tech and life sciences investment group and Vortex's lead investor, as well as remarks from Andy Burnham, Mayor of Greater Manchester. This was followed by tours of the new laboratories, technology demonstrations, and a celebratory reception.
Joe Manning, Managing Director at MIDAS, Manchester's Inward Investment Agency, added: "Vortex Biotech's decision to relocate from London to Manchester Science Park shows what Greater Manchester can offer life sciences companies looking to scale. The technology developed will enable earlier cancer detection through blood samples, strengthening Greater Manchester's position in cancer diagnostics."
"The company chose our city region because we offer direct access to the University of Manchester's research capabilities, partnerships through the NHS Manchester Foundation Trust, and a talented workforce. The expansion will create new skilled jobs in diagnostics, science, data and operations, with a commitment to developing local talent through apprenticeships and early-career pathways."
With this expansion, Vortex is positioned to accelerate its commercialization pathway and deliver non-invasive diagnostic solutions that improve outcomes for cancer patients worldwide.
Cancer vaccines enter a new era of personalized immunotherapy